Showing 3451-3460 of 6035 results for "".
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Study: Dietary Oral Zeaxanthin Decreases the Progression of Wet AMDhttps://modernod.com/news/study-dietary-oral-zeaxanthin-decreases-the-progression-of-wet-amd/2481741/Data published in the peer-reviewed journal Ophthalmology and Therapy confirmed both an earlier comparative
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and
- New Nerve Insights Could Someday Help Heal Certain Types of Blindness and Paralysishttps://modernod.com/news/new-nerve-insights-could-someday-help-heal-certain-types-of-blindness-and-paralysis/2481666/A team of UConn School of Medicine researchers report in the journal Development that at least a small population of nerve cells exist in everyone tha
- Annexon Announces Topline Data from Phase 2 Trial of ANX007 in Geographic Atrophyhttps://modernod.com/news/annexon-announces-topline-data-from-phase-2-trial-of-anx007-in-geographic-atrophy/2481637/Annexon announced topline results from its ARCHER phase 2 trial of ANX007 in patients with geographic atrophy (GA). The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion
- NEI Scientists Publish Recipe for Making Blood Vessel Cells from Patient Stem Cellshttps://modernod.com/news/nei-scientists-publish-recipe-for-making-blood-vessel-cells-from-patient-stem-cells/2481626/Researchers at NIH’s National Eye Institute have published a detailed protocol for making three cell types that are key components to form blood vessels and capillaries. The technique enables researchers to make tissues for study and potentially for future treatments. &ldquo
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development-1/2481623/Novel findings from researchers at the Brigham and Women's Hospital and Harvard Medical School, in collaboration with the Health Campus Göttingen in Germany, contradict previous notions about sugar's role in the onset of diabetic cataracts, according to a University Medical Center G&
- Researchers Discover Small-Molecule Drugs with Potential Clinical Utility in the Treatment of Retinal Diseaseshttps://modernod.com/news/researchers-discovere-small-molecule-drugs-with-potential-clinical-utility-in-the-treatment-of-retinal-diseases/2481616/In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP). The study, titled, “
- Genentech: New Vabysmo Data Suggest Greater Retinal Drying vs. Aflibercept in Wet AMD and DMEhttps://modernod.com/news/genentech-new-vabysmo-data-suggest-greater-retinal-drying-vs-aflibercept-in-wet-amd-and-dme/2481564/Genentech announced that post-hoc data indicate treatment with Vabysmo (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in wet age-related macular degeneration (AMD). In diabetic macular edema (DME), post-hoc data suggest V